PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
May 6, 2026World Journal of Clinical Medicine

Hapten Immunetherapy for Liver Cancer HBVsup+/sup 40 Years and Restores Normal HBVsup-/sup

View Full Paper
Ask AI
Bookmark
Share

Authors

BYBaofa YuJZJ Y ZhangYHYan Han

Discussion

Loading...

Member takes

Overview

Immunotherapy improves outcomes in hepatocellular carcinoma from chronic hepatitis B virus, indicating its potential role in treatment.

Key Points

  • To evaluate the impact of hapten immunotherapy on enhancing the immune response in liver cancer patients with chronic HBV infection.
  • Utilized single-cell RNA sequencing to assess tumor changes post-treatment
  • Evaluated immune cell profiles and gene expression related to MHC pathways after therapy
  • Analyzed the reduction of HBV-infection pathways and immune cell populations.
  • Significant increase in MHC II signaling pathway-related genes in B cells post-treatment
  • Reduction in HBV-infection scores and associated immune cells
  • Patients showed a drop in HBV DNA titer to zero and improved control of HCC masses.

Cite This Study

Yu et al. (2026) studied this question.

synapsesocial.com/papers/69faa25e04f884e66b533078https://doi.org/10.57237/j.wjcm.2026.01.002
View Full Paper
Ask AI
Bookmark
Share